Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction

BACKGROUND: No study has compared the cardiovascular outcomes for sodium–glucose cotransporter-2 inhibitors (SGLT2i) head-to-head against other glucose-lowering therapies, including dipeptidyl peptidase 4 inhibitor (DDP4i) or glucagon-like peptide-1 receptor agonist (GLP-1RA)—which also have cardiov...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, Jimmy, Bates, Benjamin A., Setoguchi, Soko, Gerhard, Tobias, Dave, Chintan V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999503/
https://www.ncbi.nlm.nih.gov/pubmed/36899387
http://dx.doi.org/10.1186/s12933-023-01784-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999503/
https://www.ncbi.nlm.nih.gov/pubmed/36899387
http://dx.doi.org/10.1186/s12933-023-01784-w

Ejemplares similares